Most read in Pharmacists

  • Clinical Essentials from Allergol Immunopathol (Madr)
  • 1 comment

Childhood asthma linked to prenatal paracetamol exposure

Results of a meta-analysis involving over 1 million individuals.

Read more
  • BMJ News
  • 1 comment

Check BP for 30 min to cut overtreatment

Read more
  • BMJ News
  • 1 comment

NSAIDs linked to cardiac arrest

Read more
  • BMJ News
  • 1 comment

Brain bleeding link to anti-clotting drugs

Read more
  • Clinical summaries
  • 1 comment

Vitamin D treatment response lowered by statin use

Read more
  • Clinical summaries
  • 1 comment
  • FULLTEXT

Statin escape phenomenon is for real

Read more
  • BMJ News
  • 1 comment

Obstetric anaesthesia link to cardiac arrest

Read more
  • Univadis Medical News
  • 1 comment

Google’s kidney injury deal should serve as a “cautionary tale for health care”

Read more
  • Clinical summaries
  • 1 comment
  • FULLTEXT

New consensus statement on inhaled treatment of COPD

Read more

Professional & Business

  • International Medical Press

Half of £2bn cash boost spent outside NHS

Read more
  • International Medical Press

Report: GPs not treating gynaecological patients ‘with dignity or respect’

Read more
  • International Medical Press

Bariatric surgery rationing ‘misguided’

Read more
  • International Medical Press

Scottish NHS increases access to IVF treatment

Read more
  • International Medical Press

£2bn for social care ‘not solution to the crisis’

Read more
  • International Medical Press

Less than half of women breastfeed after 2 months

Read more
View more

New in Pharmacists

Acid suppressants may worsen outcomes in IBD
  • Univadis Medical News
  • 1 comment

Acid suppressants may worsen outcomes in IBD

Link between gastric acid suppression and IBD activity explored.

Read more
EMA recommends suspension of several medicines due to unreliable study data
  • Univadis Medical News
  • 1 comment

EMA recommends suspension of several medicines due to unreliable study data

The European Medicines Agency inspection team identified a number of concerns, including misrepresentation of study data.

Read more
  • Clinical Essentials from Hematol Oncol
  • 1 comment

Biosimilar EPO-α: safe, effective in chronic lymphoid neoplasms

More than 7 in 10 patients responded.

Read more
  • Clinical Essentials from Neurology
  • 1 comment

Diabetic peripheral neuropathy: which drugs work best?

A systematic review of 106 randomized controlled trials.

Read more
  • Clinical Essentials from Ann Intern Med
  • 1 comment

ACP: treat substance abuse as a chronic condition

The American College of Physicians has issued a new policy statement.

Read more
  • Clinical Essentials from FDA
  • 1 comment

FDA approves Zejula maintenance therapy for recurrent ovarian cancer

Niraparib is the third PARP inhibitor approved for use in the US.

Read more
Sustainability and transformation plans: 4 key concerns
  • Univadis Medical News
  • 1 comment

Sustainability and transformation plans: 4 key concerns

Success of STPs is crucial for the evolution of health and care services.

Read more
  • Clinical Essentials from Pediatr Blood Cancer
  • 1 comment

Pediatric ALL: fluconazole delivers prophylaxis without increasing vincristine toxicity

Effect on cytochrome P450 isozymes may help explain results.

Read more
  • Clinical Essentials from BMC Infect Dis
  • no comment

HIV: lamivudine + dolutegravir dual therapy shows promising results

There is renewed interest in ARV-sparing strategies.

Read more
  • Clinical Essentials from Lancet Diabetes Endocrinol
  • 1 comment

Combination heart failure drug could improve glycemic control

The drug (Entresto, Novartis), combines the angiotensin receptor blocker valsartan and the neprilysin inhibitor sacubitril.

Read more
Trump's proposed healthcare Bill pulled at 11th hour
  • Univadis Medical News
  • 1 comment

Trump's proposed healthcare Bill pulled at 11th hour

Representative organisations for healthcare professionals have welcomed the outcome.

Read more
  • Clinical Essentials from Cancer
  • 1 comment

Imatinib remains drug of choice for unresectable KIT+ melanoma

Dasatinib shows limited activity in a phase 2 trial.

Read more
  • Clinical Essentials from Sci Rep
  • 1 comment

NSCLC with brain metastases: RT adds no OS benefit to icotinib

The combination does extend duration of intracranial control.

Read more
  • Clinical Essentials from PLoS One
  • 1 comment

TKIs for NSCLC: study highlights importance of monitoring EGFR mutations

Close monitoring may be able to detect resistance in a timely manner.

Read more